Human Glypican 3 / GPC3 Protein, Fc Tag (MALS verified)

用户评价
货号-规格
价格
Qty.
GP3-H5258-100ug
¥3150.00
GP3-H5258-1mg (250ug X 4)
¥20790.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    GPC3,OCI5,Glypican-3,GTR2-2,MXR7,DGSX,SDYS ,SGB,SGBS,SGBS1

  • 表达区间及表达系统(Source)

    Human Glypican 3 Protein, Fc Tag (GP3-H5258) is expressed from human 293 cells (HEK293). It contains AA Gln 25 - His 559 (Accession # P51654-1).

    Predicted N-terminus: Gln 25 & Ser 359

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    Glypican 3 Structure

    This protein carries a human IgG1 Fc tag at the C-terminus.

    This protein contains a furin-like convertase cleavage site, 355-RQYR-358, and will be partially processed into N and C-terminal fragment with calculated MW of 38.1 kDa and 49.3 kDa respectively. The protein migrates as 40 kDa, 60 kDa and 100-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 内毒素(Endotoxin)

    Less than 0.1 EU per μg by the LAL method / rFC method.

  • 纯度(Purity)

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 电泳(SDS-PAGE)

    Glypican 3 SDS-PAGE

    Human Glypican 3 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    Glypican 3 SEC-MALS

    The purity of Human Glypican 3 Protein, Fc Tag (Cat. No. GP3-H5258) is more than 90% and the molecular weight of this protein is around 170-210 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     Glypican 3 ELISA

    Immobilized Human FGF basic, premium grade (Cat. No. BFF-H4117) at 2 μg/mL (100 μL/well) can bind Human Glypican 3 Protein, Fc Tag (Cat. No. GP3-H5258) with a linear range of 4-63 ng/mL (QC tested).

    Protocol
  • Glypican 3 BATCH ELISA
  •  Glypican 3 ELISA

    Immobilized Human Glypican 3 Protein, Fc Tag (Cat. No. GP3-H5258) at 0.5 μg/mL (100 μL/well) can bind Anti-Human GPC3 Mab with a linear range of 0.8-6 ng/mL (Routinely tested).

    Protocol
  • CAR阳性表达率检测(Evaluation of CAR expression)

    FACS Analysis of Anti-GPC3 CAR Expression

     Glypican 3 CAR_T

    293 cells were transfected with anti-GPC3-scFv and RFP tag. 2e5 of the cells were first stained with B. Human Glypican 3 Protein, Fc Tag (Cat. No. GP3-H5258, 3 μg/ml) and C. human Fc tag protein control, followed by FITC-conjugated anti-human IgG Fc antibody. A. Non-transfected 293 cells and C. human Fc tag protein control were used as negative control. RFP was used to evaluate CAR (anti-GPC3-scFv) expression and FITC was used to evaluate the binding activity of Human Glypican 3 Protein, Fc Tag (Cat. No. GP3-H5258).

用户评价
发表评论

背景介绍

Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.

前沿进展

 
药物研发进展
  • 英文全称:

    Glypican-3

  • 中文全称:

    磷脂酰肌醇聚糖3

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    45 详情

  • 最高研发阶段:

    临床二期

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍